Abstract: Introduction: Triple-negative breast cancer is defined as the absence of estrogen, progesterone, and HER-2 receptors obtained by immunohistochemistry, with an incidence of 24% of newly diagnosed breast cancers. Several breast tumours have substantial lymphocytic infiltration, and tumour-infiltrating lymphocytes (TILs) are the potential surrogate markers of adaptive immune response and are positively associated with better survival in TNBC. This study examines the relationship between tumour infiltrating lymphocytes and clinicopathology in early-stage triple-negative breast cancer at HAM Hospital.